✦ LIBER ✦

A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis

✍ Scribed by Soilu-Hänninen, Merja (author);Åivo, Julia (author);Lindström, Britt Marie (author);Elovaara, Irina (author);Sumelahti, Marja Liisa (author);Färkkilä, Markus (author);Tienari, Pentti (author);Atula, Sari (author);Sarasoja, Taneli (author);Herrala, Lauri (author);Keskinarkaus, Irma (author);Kruger, Johanna (author);Kallio, Timo (author);Rocca, Maria A. (author);Filippi, Massimo (author)

Book ID: 124073520
Publisher: BMJ Publishing Group
Year: 2012
Tongue: English
Weight: 153 KB
Volume: 83
Category: Article
ISSN: 0022-3050
DOI: 10.1136/jnnp-2011-301876

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomised, double blind, placebo cont

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon -1b in patients with multiple sclerosis

✍ Soilu-Hanninen, M.; Aivo, J.; Lindstrom, B.-M.; Elovaara, I.; Sumelahti, M.-L.; 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 153 KB

Daclizumab in active relapsing multiple

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

✍ Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jac 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 456 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

A randomised double-blind placebo-contro

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

✍ P. Loiseau; A.W.C. Yuen; B. Duché; T. Ménager; M.C. Arné-Bès 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Efficacy and safety of lamotrigine (LTG) as add-on therapy was assessed in a randomised double-blind placebo-controlled trial of this drug in 23 adult patients with refractory partial seizures. Fifteen patients showed an improvement on LTG treatment, with a greater than 50% decrease in total seizure

Interferon beta-1a for brain tissue loss

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

✍ Massimo Filippi; Marco Rovaris; Matilde Inglese; Frederik Barkhof; Nicola De Ste 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 181 KB

Safety and efficacy of fingolimod in pat

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

✍ Calabresi, Peter A; Radue, Ernst-Wilhelm; Goodin, Douglas; Jeffery, Douglas; Ram 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 290 KB